Year: 2025
Type: article
Study design: Case Report
Abstract: Immune checkpoint inhibitors (ICI), particularly antibodies targeting programmed death receptor-1 (PD-1) and its ligand, programmed death-ligand 1, have been rarely associated with the development of immune-mediated diabetes mellitus. To the best of our knowledge, we report the first published case of immune-mediated diabetes mellitus associated with dostarlimab-a monoclonal antibody targeting PD-1-in a 78-year-old woman diagnosed with endometrial adenocarcinoma and persistent peritoneal disease. Following six cycles of dostarlimab, she presented with diabetic ketoacidosis. Despite negative autoimmune antibodies, her relatively low HbA1c and C-peptide levels together with her clinical presentation were highly suggestive of ICI-induced diabetes mellitus. Following stabilization with intravenous fluids and insulin infusion, she was transitioned to a basal-bolus insulin regimen. Dostarlimab was discontinued, and restaging showed resolution of peritoneal disease. This case emphasizes the importance of early detection and management of ICI-induced diabetes mellitus.
Source: Acta Médica Portuguesa
DOI: 10.20344/amp.23618
Authors: Andreia Pataco, Bruna Pimentel, Margarida Lagarto, Adélia Félix, Clara Cunha
Institution: Hospital do Divino Espírito Santo
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4416008187